Sign inJoin waitlistJoin the waitlist

Xiaolin Wei

Neurology Residency · Zucker School of Medicine at Hofstra/Northwell

Credentials: · · ·

History

Neurology
Zucker School of Medicine at Hofstra/Northwell
2025–Present
Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
2007–2011

Research

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore):…
The Lancet · 2024 · 270 citations
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy
Clinical Cancer Research · 2021 · 169 citations
Evolution of myeloid-mediated immunotherapy resistance in prostate cancer
Nature · 2025 · 153 citations

Bradley McGregor
22 papers
Toni Choueiri
20 papers
LH
Lauren Harshman
15 papers
Rana McKay
15 papers · 4 as a resident
Atish Choudhury
12 papers
Kerry Kilbridge
10 papers
Lawrence Fong
10 papers
Eli Van Allen
9 papers
Mark Pomerantz
9 papers
David Braun
8 papers
GS
Guru Sonpavde
8 papers
Jack Steinharter
8 papers

Clinical trials

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Principal investigator · Active not recruiting · Phase 2
Xiao X. Wei, MD
2020–2026
A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
Principal investigator · Completed · Phase 1
Dana-Farber Cancer Institute
2019–2021
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
Study chair · Active not recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2022–2030
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2025–2032